Heartbeats, no strings attached: EBR’s big step toward FDA approval
EBR Systems (ASX:EBR) has announced that the FDA will conduct a Pre-Approval Inspection of its manufacturing facility during the week commencing 6 January 2025.
Read More
Ebr Systems Inc
EBR Systems is driven to deliver superior treatment for millions of patients suffering from cardiac rhythm diseases by developing safe, clinically superior, cost-effective and reliable therapies using wireless cardiac stimulation.
Videos
Videos coming soon for Ebr Systems Inc.
News
EBR – Morgans rates the stock as Speculative Buy
The target falls to $1.38 from $1.84 to reflect increased volatility and higher funding costs. The Speculative Buy rating is maintained.
Read More
